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ABSTRACT 
CD4
+
CD25
+
 regulatory T cells (Treg) play a crucial role in the regulation of immune 
responses. While many mechanisms of Treg suppression in vitro have been described, the 
mechanisms by which Treg modulate CD8+ T-cell differentiation and effector function in 
vivo are more poorly defined. It has been proposed, in many instances, that modulation of 
cytokine homeostasis could be an important mechanisms by which Treg regulate adaptive 
immunity, however, direct experimental evidence is sparse. Here we demonstrate that 
CD4+CD25+ Treg, by critically regulating IL-2 homeostasis, modulate CD8+ T cell effector 
differentiation. Expansion and effector differentiation of CD8+ T cells is promoted by 
autocrine IL-2 but, by competing for IL-2, Treg limit CD8+ effector differentiation. 
Furthermore, a regulatory loop exists between Treg and CD8+ effector T cells where IL-2 
produced during CD8+ T-cell effector differentiation promotes Treg expansion. 
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INTRODUCTION 
CD4+CD25+Foxp3+ regulatory T cells (Treg) maintain immune homeostasis by 
limiting T-cell responses to self, environmental and pathogen-associated antigens and by 
modulating innate immune responsiveness. The critical role of Treg in preventing 
autoimmunity is highlighted when Treg are developmentally absent or depleted (1-3). In 
vivo, the modulatory effects of Treg on adaptive immunity are likely mediated through 
suppression of both CD4+ and CD8+ T cells. But, while Treg suppression of CD4+ T cell 
responses has been widely studied both in vitro and in vivo, modulation of CD8+ T cell 
responses by Treg is less well understood. Depleting Treg promotes CD8+ T-cell-dependent 
responses such as virus and tumour clearance (4, 5). In many of these studies, however, 
whether Treg depletion affects primarily the afferent phase of CD8+ T-cell expansion and 
effector differentiation, or, the later efferent phases has been largely undistinguished.  
In CD4+ T-cell dependent autoimmune responses, Treg limit both T-cell priming in LN 
(6) and effector activity at sites of inflammation (7). For CD8+ T cells, it has been elegantly 
shown, in a tumour setting, that Treg directly inhibit CD8+ T-cell-mediated cytolysis 
through, for example, TGF--dependent inhibition of degranulation (8, 9) without 
modulating effector differentiation. However, in settings that lead to strong priming, such as 
vaccination, Treg can restrain CD8+ T cell expansion (10). Such disparate observations could 
reflect differences between T-cell activation occurring under either weak or strong innate 
immune cell or APC activation respectively. It is, however, also possible that Treg function is 
enhanced by T cells undergoing effector differentiation in response to strongly immunogenic 
T-cell priming facilitating Treg control under these conditions.  
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Mechanisms of CD4+ T-cell inhibition by Treg in vitro have been well described 
(reviewed in (11, 12) but in vivo mechanisms of CD8+ T-cell suppression are poorly 
understood.  Consumption of IL-2 is often proposed as a mechanism of Treg suppression. 
Evidence is strong that CD4+ T-cell effector function is inhibited in vitro by this mechanism 
(13, 14), but direct experimental evidence for this mechanism in vivo is lacking.  Existing 
evidence is correlative, which most likely reflects the technical challenge of blocking IL-2 
activity without disturbing T-cell developmental homeostasis and studies have relied on 
knockout or immunodeficient mice in which homeostasis of T cells and cytokines is highly 
perturbed. Recent studies have shown that both Treg and CD8+ T cells are exquisitely 
sensitive to modulation of IL-2 homoeostasis in vivo (15-17). Emerging evidence implicates 
alterations in IL-2 homeostasis in development of a range of autoinflammatory responses (18-
20). Given the importance of CD8 T-cell responses in tumour clearance and autoimmunity 
we investigated the inter-relationship of IL-2, Treg and CD8+ T-cell effector differentiation. 
We demonstrate, in vivo, regulation of CD8+ effector differentiation by Treg-mediated 
modulation of IL-2 bioavailability.  
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RESULTS  
Regulatory T cells restrain CD8+ T cell expansion and inhibit effector differentiation 
To define the influence of Treg on CD8+ T cells, ovalbumin (OVA)-specific TCR 
transgenic CD8+ T cells (OT-I) were transferred and recipient mice immunized with or 
without Treg depletion. Immunization with OVA/QuilA led to rapid expansion of OT-I T 
cells in the draining (inguinal) LN which was followed by migration of differentiated 
effectors to spleen (Fig. 1A,B) indicating migration of differentiated effectors from the site of 
priming. After transient accumulation in both sites, the number of OT-I T cells waned (Fig. 
1A,B), consistent with normal post-expansion population contraction. Administration of 
CD25 effectively depleted Treg throughout the course of the experiments (Suppl. 1A,B) and 
substantially increased OT-I T-cell expansion, prolonged their accumulation in draining LN 
and increased their accumulation in spleen (Fig. 1A,B). When Treg were depleted, more OT-I 
T cells were recovered from mice challenged with OVA twenty-one days after immunization 
(Fig. 1D), consistent with increased memory cell formation. Thus, after immunization, Treg 
modulated OT-I T-cell expansion and memory formation as observed previously for other 
CD8+ T-cell responses (10). 
Treg modulate immune responses to self-antigens and, in so doing, prevent 
autoimmune disease (2, 3). Current paradigms suggest steady-state DC tolerise T cells, but 
loss of Treg converts tolerogenic to immunogenic T-cell activation under steady-state 
conditions (21). Neonatal thymectomy (nTx) is classically used to limit Treg development 
and promotes autoimmunity (1). Therefore, we used 11c.OVA mice in which OVA is 
expressed by DC (22), to test whether nTx modulated steady-state DC activation of naïve 
CD8+ T cells in order to confirm Treg control of afferent CD8+ T-cell responses. In the 
11c.OVA model, transferred OT-I T cells undergo proliferation and population expansion 
followed by deletion and, ultimately, tolerance (22). The number of B220+ B cells or 
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CD11b+ myeloid cells in blood or spleen of 11c.OVA mice was not altered by nTx, whereas 
Treg, CD8+ and CD4+ T cells were all numerically reduced relative to sham-Tx controls 
(Suppl. 1C). As reported (1), Treg were not completely absent, but additional treatment with 
antiCD25 resulted in almost complete ablation of Treg from nTx 11c.OVA mice (Supp. 
1C).  Neither thymectomy nor anti-CD25-mediated depletion of Treg alone altered the 
kinetics or extent of OT-I T-cell expansion and contraction in 11c.OVA mice (Fig. 1E).  
Anti-CD25 treatment of nTx 11c.OVA mice substantially increased expansion and delayed 
contraction of the OT-I T-cell population (Fig. 1E), and substantially increased total IFN-
producing OT-I T cells relative to controls (Fig. 1F). Differentiating CTL show 
hierarchical production of IFN-, TNF and IL-2 and polyfunctional CTL are considered 
higher-quality effectors.  Consistent with increased effector differentiation, the proportion of 
IFN-+/TNF+ and IFN-+/IL-2+ OT-I T cells was much greater when Treg were depleted 
(Fig. 1G,H).  Together these data demonstrate that, under immunogenic conditions, Treg 
modulate CD8+ T-cell expansion and effector differentiation.  
 
Circulating IL-2 is increased during CD8+ T-cell activation in the absence of Treg 
Interleukin-2 is crucial not only for the function and maintenance of Treg but also plays 
an important role in CD8+ T cell homeostasis, priming and memory formation. IL-2 
production is a hallmark of differentiating CD8+ effector T cells and production is lost as 
terminal effector status is acquired. As the effect of Treg depletion was most profound during 
the phase of effector differentiation, we investigated the role of IL-2. We first defined IL-2R 
expression on OT-I T cells. After immunization, CD122 (IL-2R) was expressed by almost 
all OT-I T cells within 2d and then remained stably expressed (Fig 2A, upper panel). CD25 
(IL-2R), on the other hand, was transiently upregulated by OT-I T cells 1d after OVA 
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immunization, then returned to low levels within 2d (Fig. 2A, lower panel).  In contrast, 
CD25 expression by Treg did not change after immunization. Thus, during the effector 
differentiation phase, CD8+ OT-I T cells primarily express the  low-affinity IL-2R. Given 
that the high affinity IL-2R, comprised of the  chains, has a 100-fold higher affinity for 
IL-2 and was expressed at higher levels by Treg than OT-I T cells, Treg might effectively 
compete with OT-I T cells for IL-2. Alternatively, removal of Treg could increase CD8+ T-
cell effector differentiation by IL-2-independent mechanisms. To distinguish between these 
possibilities we next looked at IL-2 production by differentiating CD8+ T cells and its 
homeostasis in the presence and absence of Treg. The total number of IL-2-producing OT-I T 
cells accumulating in spleens of OVA-immunized or nTx 11c.OVA OT-I recipients at the 
peak of the expansion response was substantially increased by Treg depletion (Fig 2B,C) 
consistent with the increase in polyfunctional OT-I T cells in the absence of Treg (Fig. 1).  
Given that the number of IL-2 producing OT-I T cells was increased we next determined 
whether circulating IL-2 was increased in the absence of Treg.  Although normally tightly 
regulated to almost undetectable levels, IL-2 was detected in the serum of six of eight OVA 
immunized Treg-depleted mice (Fig. 2D) and reached high levels in nTx OT-I recipients 
(Fig. 2E).  Thus IL-2 levels were markedly increased, either from increased differentiation of 
OT-I T cells or decreased consumption in the absence of Treg. 
 
Increased expansion of CD8+ T-cell in the absence of Treg is IL-2-dependent. 
To test the possibility that increased IL-2 availability in the absence of Treg promoted 
expansion and differentiation of OT-I T cells we compared accumulation of OT-I T cells in 
spleens of OVA-immunized OT-I recipients or nTx 11c.OVA OT-I recipients depleted of 
Treg with or without additional IL-2 blockade. To achieve IL-2 blockade we treated mice 
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with the combination of two IL-2 mAb (S4B6, JES6-1) that alternately block the high- and 
low-affinity IL-2R binding sites respectively of the IL-2 molecule (15). In the absence of 
Treg depletion, IL-2 blockade had little if any effect on OT-I T cell accumulation in spleen 7 
days after immunization (Fig. 3A). As expected, depletion of Treg promoted OT-I T-cell 
accumulation in spleens of OVA-immunized recipient mice and this was completely reversed 
by IL-2 blockade. Similarly, in nTx 11c.OVA mice, IL-2 blockade almost completely 
abrogated the additional OT-I T-cell accumulation in spleen resulting from Treg depletion 
(Fig. 3B). Since CD25 expression is not strictly limited to Treg and is transiently expressed 
by activated OT-I T cells (Fig. 2) we employed two further strategies to verify that our results 
reflected Treg control of CD8+ T cell expansion and effector differentiation, rather than off-
target effects of CD25 blockade.  
In DEREG mice expressing human diphtheria toxin (DT) receptor targeted by the 
FoxP3 promoter, FoxP3+ Treg are depleted by administration of DT (3).  Accumulation of 
OT-I T cells in DEREG recipient spleens seven days after OVA/QuilA immunization (Fig. 
3C) was significantly increased by administration of DT and to a level similar to that 
following Treg depletion with anti-CD25 mAb (e.g. Fig. 3A).  IL-2 blockade significantly 
reduced the DT-induced additional OT-I T-cell accumulation (Fig. 3C). Folate receptor 4 
(FR4) is an alternate Treg-specific marker expressed at high levels by CD25
hi 
Treg.  Thus, 
anti-FR4 mAb depletes CD25
hi
 Treg, as does anti-CD25, but not effector T cells (23). 
Depletion of Treg using anti-FR4 significantly increased the number of OT-I T cells in spleen 
seven days post-immunization (Fig. 3D) and this was completely prevented by IL-2 blockade 
(Fig. 3D). As increased OT-I accumulation after DT treatment of DEREG mice, which 
depletes both CD25+FoxP3+ and CD25-FoxP3+ Treg, was not completely reversed by IL-2 
blockade it is possible that, and consistent with IL-2 uptake via the high affinity  receptor, 
only CD25
hi
 Treg modulate IL-2 availability.  In mice depleted of Treg using either DT 
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treatment of DEREG mice or anti-FR4 antibody, serum IL-2 was increased relative to 
undepleted mice (Fig 3E,F) similar to the increase seen after anti-CD25 treatment (Fig 2D,E) 
confirming that IL-2 availability was modulated by the presence of Treg.  In contrast, 
depletion of Treg by anti-CD25, anti-FR4 treatment or DT treatment of DEREG mice did not 
lead to significant accumulation of IL-2 in serum in the absence of OT-I transfer and OVA 
immunisation (Fig. 3G).  
The conditions tested to this point reflect a CD8+ T-cell response corresponding in 
magnitude range to a potent antiviral response.  Under these conditions it is possible large 
amounts of IL-2 could be produced, possibly over-representing the importance of Treg 
modulation of IL-2. To determine whether alteration of IL-2 homeostasis by Treg also 
modulated less potent responses where less IL-2 may be produced we transferred 100-fold 
fewer OT-I T cells.  Even under these conditions depletion of Treg boosted accumulation of 
OT-I T cells and this was reversed by blockade of IL-2 (Fig 3H).  
 
Effector differentiation of CD8+ T cells modulates IL-2-mediated Treg homeostasis  
As Treg numbers and function are highly dependent on IL-2 (17), it is possible that IL-
2 produced during CD8+ T cell effector differentiation could feedback on Treg homeostasis. 
Neonatal thymectomy results in a partial, but stable, Treg deficiency in 11c.OVA mice which 
can be further manipulated by depleting (Fig. 4A, Suppl. 1) or adoptively transferring Treg 
therefore providing an ideal system in which to monitor influences on Treg homeostasis. 
Adoptive transfer of OT-I T cells to nTx 11c.OVA mice resulted in a rapid and significant 
increase in the total number of splenic Treg and restored Treg to levels equivalent to that in 
shamTx controls (Fig. 4A, days 0, 1, 3) whereas transfer of irrelevant antigen-specific CD8+ 
(gBT-I) T cells did not. In shamTx 11c.OVA mice, Treg numbers did not change after 
adoptive transfer of OT-I T cells (Fig. 4A). Treatment with CD25maintained Treg at low 
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levels regardless of whether 11c.OVA recipients were nTx or not (Fig. 4A) indicating a 
failure of Treg restoration either due to depletion or functional inhibition of high affinity IL-2 
signalling. Therefore, inducing effector differentiation of antigen-specific CD8+ T cells 
resulted in IL-2 production (Fig. 2B) and led to concurrent expansion of Treg that was 
preventable by blockade of CD25. To determine whether this truly reflected an IL-2-
dependent expansion of Treg, OT-I or irrelevant-specificity CD8+ (gBT-I) T cells were 
transferred to nTx 11c.OVA mice with or without IL-2 blockade. Treg expanded after 
transfer of OT-I but not antigen-irrelevant gBT-I T cells and this was completely prevented 
by IL-2 blockade (Fig. 4B).  
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DISCUSSION 
Regulatory T cells are important controllers of adaptive and innate immune responses. 
In vitro mechanisms of CD4+ T-cell inhibition by Treg are well described (11, 12), but 
suppression mechanisms in vivo, particularly of CD8+ T-cell responses, are poorly defined. 
Here we provide compelling direct evidence that Treg inhibit CD8+ T cell expansion and 
effector differentiation in vivo by limiting IL-2 availability.  
Release of Treg control of afferent effector differentiation or the efferent function of 
terminally-differentiated cytotoxic T lymphocytes (CTL), or possibly both, may underlie 
promotion of CD8+ T-cell-dependent responses such as virus and tumour clearance that 
occurs after Treg depletion (4, 5).  That Treg suppress CD8+ T-cell effector responses by 
inhibiting CTL degranulation is well established (8, 9).  Our results now clearly demonstrate 
that Treg also strongly modulate CD8 T-cell expansion and effector differentiation and this is 
supported by recent studies from others (24, 25).  IL-2 crucially governs homeostasis of 
effector and regulatory T cells and both cell types are exquisitely sensitive to modulation of 
IL-2 availability in vivo (15).  The present study shows, when present, Treg effectively 
modulate the bioavailability of IL-2 as CD8+ T cells expand and differentiate after 
immunogenic stimuli. Furthermore, where Treg uptake of IL-2 is blocked, here achieved by 
anti-CD25 treatment or Treg depletion, CD8+ T cells are able to expand without Treg 
competition and concomitantly effector differentiation is also promoted. That availability of 
IL-2 could promote CD8+ effector differentiation in the absence of Treg is supported by 
demonstrations that increased IL-2 signalling in CD8+ T cells, either in the form of IL-2/anti-
IL-2 complexes (15) or prolonged IL-2R signalling (26), promotes their responsiveness.  
Many mechanisms have been proposed to underlie suppression of T-cell responses in-vivo by 
Treg.  However, it is largely unclear which of these mechanisms apply to CD8+ T-cell 
responses.  Historical and more recent evidence indicates that CD8+ T cells are exquisitely 
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sensitive to the effects of IL-2 availability but whether, and by how much, Treg might control 
CD8+ responses by modulating IL-2 was previously unclear.  In DEREG mice, where DT 
depletes both FoxP3+CD25+ and FoxP3+CD25- Treg, the observation that blockade of IL-2 
incompletely reversed the effect of Treg depletion suggests release from both IL-2-dependent 
and IL-2-independent suppression.  Conversely, when anti-CD25 or anti-FR4 mAb were 
used, only FoxP3+CD25+ Treg but not Foxp3+CD25- were depleted and enhanced OT-I 
expansion was virtually all IL-2-dependent.  We propose this data supports a model where, 
by virtue of their high-affinity IL-2R (CD25) expression, FoxP3+CD25+ Treg modulate IL-2 
homeostasis whereas FoxP3+CD25- Treg appear able to exert regulation independent of this. 
Further to understanding how Treg inhibit CD8+ T-cell effector differentiation, our 
findings highlight the complex interplay between effector differentiation and Treg 
homeostasis mediated by IL-2 signals.  We found that IL-2 produced during CD8+ T-cell 
effector differentiation induced homeostatic expansion of Treg which can then contribute to a 
feedback loop regulating afferent CD8+ T-cell responses.  These data suggest that the 
‘rheostat’ for Treg number is determined by the overall population of effector and naïve T 
cells and the extent of their activation with the ‘set-point’ being readily adjusted as IL-2 
becomes available from differentiating effector T cells. In our studies this significantly 
modulated Treg numbers, most likely through proliferation of pre-existing Treg although this 
was not directly tested. Such a proposal is supported by studies in which the abundance of IL-
2 in vivo has been increased by administration (19, 27), enforced expression (16) or by 
increasing bioavailability to the  high affinity receptor (28).  Previously, it has been 
widely observed that induction of antigen-specific immune responses can promote Treg 
function contributing to control of antigen-specific responses, but a mechanism for this 
remains poorly-defined.  We show that feed-forward, via IL-2, from differentiating effector 
CD8+ T cells plays an important role in expanding Treg that can subsequently limit CD8+ 
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effector responses, indicating this mechanisms as an important contributor. Therefore, IL-2 
produced during effector T cell differentiation is a crucial component of efficient regulation 
of adaptive immunity.  The importance of this mechanism for immune homeostasis is 
confirmed by studies in which Treg control over pathogenic self-reactive T-cell responses is 
promoted by non-specific or pathogen activation of effector T-cell responses (29, 30) or 
provision of exogenous IL-2 (19, 28, 31). Conversely, when IL-2 availability is limited, 
through genetic perturbations for instance, autoinflammation ensues (18-20)   
In summary, using a novel approach, we provide direct experimental evidence that 
consumption of IL-2 is a key in vivo mechanism by which Treg control CD8+ T-cell effector 
differentiation.  Altered numbers or dysfunction of Treg will thus impact CD8+ effector 
responses in tumor and viral immunity as well as autoimmune disease.  
  
  
14 
MATERIALS AND METHODS 
Mice 
Mice were from the Animal Resources Centre (Perth, WA, Australia) or bred and 
maintained at the Princess Alexandra Hospital Biological Research Facility (Brisbane, QLD, 
Australia). OT-I mice (32) carrying a transgenic TCR for H-2K
b
/OVA257-264 were bred with 
C57BL/6.SJLptprca mice to generate CD45.1+ OT-I cells. gBT-I mice carry a transgenic 
TCR for H-2K
b
/HSV-1 glycoprotein B498-505 (33) and were a kind gift from Dr Francis 
Carbone (University of Melbourne, Australia). CD11c.OVA (22) and DEREG (3) mice have 
been described. All animal experiments were approved by an institutional animal ethics 
committee.  
 
Thymectomy and Treg depletion 
Three-day neonatal thymectomy was performed as described
 
(34). Neonates were 
anesthetised on ice and thymic lobes removed by suction through a sternal incision. Sham-
thymectomised mice were treated identically but without thymus removal. Peripheral blood 
leukocytes were screened at 4-6 weeks of age and successfully thymectomised mice were 
selected based on peripheral blood lymphopenia (<9% of normal CD4+ T cells). CD25
+
 cells 
were depleted using CD25 (PC61, 1mg) three days prior to adoptive transfer of T cells and 
every 3 days thereafter for the course of the experiment.  Isotype controls were treated 
identically with phytochrome (MAC-4).  Anti-FR4 was administered 2 days before OT-I 
transfer and every 3 days thereafter. For the memory and recall experiments, mice were 
treated with a single dose of CD25 (PC61, 1mg) three days prior to adoptive transfer and 
immunization. In some studies, DEREG and control mice were treated with DT as described 
(3).   
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Antibodies and flow cytometry  
Unless stated, mAb for FACS were from Biolegend (San Diego, CA, USA), BD (San 
Jose, CA) or grown, purified and conjugated in-house. Anti-CD25 (PC61, rat IgG1) and anti- 
phytochrome (Avena sativa) (MAC49, rat IgG1), were purified from hybridoma supernatants 
in house, anti-FR4 mAb was kindly supplied by Prof Shimon Sakaguchi (Kyoto University, 
Japan) and anti-IL-2 for in vivo blockade (JES6-1, S4B6) were purchased from BioXcell 
(Lebanon, NH, USA). Mouse/rat FoxP3 staining set and ELISA mAb were from eBioscience 
(San Diego, CA, USA) used in accordance with instructions. Flow-Count Fluorospheres were 
from Beckman-Coulter Inc. (Fullerton, CA, USA). Cells were stained and analyzed as 
described previously (22).  For analysis of Treg depletion by anti-CD25 (PC61), cell 
suspensions were stained using an alternate anti-CD25 clone (7D4, Cymbus Biotechnology) 
for FACS analysis. 
 
Cell preparation, transfer and immunization 
Brachial, axillary, inguinal and mesenteric LN were collected from CD45.1+ OT-I or 
gBT-I mice and CD8+ T- cells purified (>90% CD8+, <3% CD4+) by negative selection 
using magnetic beads according to the manufacturers instruction (Miltenyi Biotec, Auburn, 
CA) and 2 x 10
6
 cells injected i.v. In a small number of experiments OT-I donor mice were 
treated with CD25 and bulk LN cells containing 2x 106 CD8+ (OT-I) T cells transferred. In 
a small number of experiments OT-I T cells were prepared as described and 2x10
4
 transferred 
i.v. Mice were immunized s.c. at the tail-base with OVA/QuilA (100ug OVA [Grade V, 
Sigma], 20ug QuilA [Soperfos Biosector DK-Vedback, Denmark]). 
 
IL-2 blockade and ELISA 
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The mAb S4B6 and JES6-1A12 individually bind high or low-affinity IL-2R binding 
sites on the IL-2 molecule (15) and were injected i.p. (100 - 200ug daily) in combination to 
achieve IL-2 blockade in vivo. For ELISA, serum was prepared from blood obtained by 
cardiac puncture. ELISA plates were coated with IL-2 (JES6-1A12), washed, blocked and 
incubated with serum and standards overnight. Biotinylated IL-2 detection mAb (JES6-
5H4) was followed by avidin-horseradish peroxidise (Sigma, St Louis) subsequently 
visualised with TMB (Biolegend, San Diego, CA) according to standard protocols.  
 
Statistical analyses 
Students t-test was used for comparison of means and one way ANOVA followed by 
Newman-Keuls post test (GraphPad Software,
 
San Diego, CA) for multiple pairwise 
comparisons.  
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FIGURE LEGENDS 
Figure 1: Regulatory T cells restrain CD8+ expansion and effector differentiation 
(A-C) CD45.1+ OT-I T cells were transferred to anti-CD25 or isotype-treated C57Bl/6 
mice immunized with OVA/QuilA at the time of transfer.  At the indicated time points, 
inguinal lymph nodes (A) or spleens (B,C) were collected and OT-I number determined by a 
FACS counting assay and intracellular cytokine staining performed.  (D) CD45.1+ OT-I T 
cells were transferred to anti-CD25 or isotype-treated C57Bl/6 mice immunized with 
OVA/QuilA at the time of transfer and 21 days later. A further 7 days later spleens were 
collected and the total number of OT-I cells determined using a FACS counting assay.   (E-
H)  CD45.1+ OT-I T cells were transferred to nTx or sham-Tx 11c.OVA mice treated with 
either anti-CD25 or isotype-control mAb.  At the indicated time points (E,F) or 3 days after 
transfer (G,H), spleens were collected and OT-I T cell number determined by a flow-
cytometric counting assay and  intracellular cytokine staining performed.  Data depict mean ± 
SEM or individual values for 4 to 10 mice for each time point (A, B, C) pooled from a 
minimum of 2 experiments except inguinal LN one day post-transfer where 2 mice from a 
single experiment are represented and (D-H) 4-6 mice per group pooled from 2-3 individual 
experiments. *: p<0.05, **: p<0.01, ***: p<0.001. 
 
Figure 2: Systemic IL-2 is increased in the absence of Treg 
(A) CD45.1+ OT-I T cells were transferred to C57Bl/6 mice immunized with 
OVA/QuilA and at the indicated time points expression of CD25 and CD122 by OT-I T cells 
was determined by FACS.  (B,D) CD45.1+ OT-I T cells were transferred to C57Bl/6 mice 
treated with anti-CD25 or isotype control mAb and immunized or not with OVA/QuilA at the 
time of transfer.  Seven days later  spleens were collected and the number of IL-2 producing 
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OT-I T cells determined by intracellular cytokine staining and a FACS counting assay (B) or 
serum collected and IL-2 concentration determined by ELISA (D).  (C,E) CD45.1+ OT-I T 
cells were transferred to anti-CD25 or isotype-treated nTx or sham-Tx 11c.OVA mice.  Three 
days later spleens were collected and the number of IL-2 producing OT-I T cells determined 
by intracellular cytokine staining and a FACS counting assay (C) and serum collected and IL-
2 measured by ELISA (E).  Limit of IL-2 detection is denoted by the horizontal dashed line.  
Data are representative of: (A) 4 mice from 2 individual experiments or (B-E) pooled from at 
least 2 separate experiments each point representing an individual mouse. 
 
Figure 3: Increased expansion and effector differentiation in the absence of Treg is IL-
2-dependent.  
(A) CD45.1+ OT-I T cells (2x 10
6
) were transferred to anti-CD25 or isotype-treated 
C57Bl/6 mice immunized or not with OVA/QuilA at the time of transfer and additionally 
administered anti-IL-2 (JES6.1 plus S4B6) or PBS as indicated.  Seven days later spleens 
were collected and the total number of OT-I T cells determined by FACS counting assay.  (B) 
CD45.1+ OT-I T cells were transferred to anti-CD25 or isotype-treated nTx 11c.OVA mice 
administered either anti-IL-2 or PBS.  Three days later spleens were collected and the total 
number of OT-I T cells determined by FACS counting assay.  (C,E) CD45.1+ OT-I T cells 
were transferred to DEREG or non-transgenic mice treated or not with DT, anti-IL-2 or PBS 
and immunised with QuilA at the time of transfer.  Seven days later spleens (C) were 
collected and the total number of OT-I T cells determined by FACS counting assay and  
serum IL-2 determined by ELISA (E).  (D,F) CD45.1+ OT-I T cells were transferred to 
C57Bl/6 mice treated or not with anti-FR4 and anti-IL-2 and immunised with OVA/QuilA at 
the time of transfer.  Seven days later (D) spleens were collected and the total number of OT-
I T cells determined by FACS counting assay and serum IL-2 determined by ELISA (F).  (G)  
  
23 
C57Bl/6 mice were treated or not with anti-CD25 or anti-FR4. DEREG mice were treated 
with DT and 7days later serum collected and IL-2 measured by ELISA.  (H) CD45.1+ OT-I T 
cells (2x 10
4
) were transferred to anti-CD25 or isotype-treated C57Bl/6 mice administered 
either anti-IL-2 or PBS and immunized with OVA/QuilA at the time of transfer. Seven days 
later spleens were collected and the total number of OT-I T cells determined by FACS 
counting assay.  Data are pooled from at least two separate experiments and each data point 
portrays an individual mouse. 
 
Figure 4: Effector differentiation of CD8+ T cells induces IL-2-dependent Treg 
expansion. 
(A) CD45.1+ OT-I or CD45.1+ gBT-I T cells were transferred to nTx or sham-Tx 
11c.OVA mice treated with anti-CD25 or isotype control mAb. At the indicated time points, 
spleens were collected and the number of CD4+CD25+FoxP3+ Treg determined by FACS 
counting assay.  (B) CD45.1+ OT-I or CD45.1+ gBT-I T cells were transferred to nTx 
11c.OVA mice treated with anti-IL-2 (JES6.1 plus S4B6) or PBS as indicated. Three days 
after transfer spleens were collected and the number of CD4+CD25+FoxP3+ Treg 
determined by flow cytometry.  Data are (A) mean ± SD (n=4 to 7/group) or (B) individual 
values pooled from 2-3 experiments. 
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Supplementary Figure 1.  
A) C57Bl/6 mice were treated with anti-CD25 (PC61) or isotype control (MAC4) antibody and 
the number of CD4+CD25+FoxP3+ Treg in spleens determined by flow cytometry 3 days later. 
B) 11c.OVA mice were treated with anti-CD25 (PC61) every 3 days commencing 3 days prior to 
transfer of OT-I T cells.  At the indicated times the number of CD4+CD25+FoxP3+ Treg in 
spleens was determined by flow cytometry. C) 11c.OVA mice were thymectomised at 3 days of 
age.  5-6 weeks later, thymectomised mice were treated with anti-CD25 or not and 3 days later the 
number of B220+, CD11b+, CD3+CD8+, CD3+CD4+ and CD4+CD25+FoxP3+ cells in spleens 
determined by flow cytometry.  
 
 
